Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BGMA Warns No-Deal Brexit Will Harm Depleted UK Stockpile

As European Governments Brace For Possible Second Wave Of COVID-19

Executive Summary

While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.

You may also be interested in...



UK Promises Reduced Trial Burden For Biosimilars

New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.

Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

UK Supply Chain Disruption Due To Closed Borders Remains A Concern

The BGMA has emphasized the importance of prioritizing transport of medicines across borders, at the same time as it has praised decisions by the UK competition authority and European Commission to relax rules on co-ordinating to facilitate the supply of medicines.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel